Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 6Peritoneal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Appendiceal Neoplasms 3Anus Neoplasms 2Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Peritoneal Diseases 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Necrosis 1Male Urogenital Diseases 1HIV Infections 1Gastrointestinal Neoplasms 1Female Urogenital Diseases 1Anal Canal Carcinoma 1

Interventions

Capecitabine 22Oxaliplatin 19Fluorouracil 16Radiotherapy 11Leucovorin 10Cetuximab 9Nivolumab 7Bevacizumab 6sintilimab 5Specimen Handling 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Irinotecan 5Folfox protocol 5trifluridine tipiracil drug combination 4pembrolizumab 4Surgical Procedures, Operative 4encorafenib 3X-Rays 3Trastuzumab 3Surveys and Questionnaires 3Sigmoidoscopy 3Radiation 3Pemetrexed 3Gemcitabine 3Endoscopy 3Control Groups 3Consolidation Chemotherapy 3Cisplatin 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Mitomycin × 90 days × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡